Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

HCV NS3 recombinant antigens and mutants thereof for improved antibody detection

a technology of recombinant antigens and mutants, applied in the field of polypeptides, can solve the problems of ineffective treatment in all cases, formation of insoluble inclusion bodies, no vaccine available, etc., and achieve the effects of increasing redox stability, and increasing immunoreactivity against hcv

Inactive Publication Date: 2017-11-16
ABBOTT LAB INC
View PDF3 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The patent is about a new type of Hepatitis C virus (HCV) antigen that is more stable and can better stimulate the body's immune system. This is achieved by adding specific domains from the protein NS3 helicase and improving its redox stability. The resulting antigen is more effective for diagnosing and potentially treating HCV infections.

Problems solved by technology

The current recommended treatment for HCV infections is a combination of interferon and ribavirin drugs, however the treatment is not effective in all cases and liver transplantation is indicated in hepatitis C-related end-stage liver disease.
At present, there is no vaccine available to prevent HCV infection, therefore all precautions to avoid infection must be taken.
The expression of this fusion protein in E. coli via a temperature inducible system results in the formation of insoluble inclusion bodies.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • HCV NS3 recombinant antigens and mutants thereof for improved antibody detection
  • HCV NS3 recombinant antigens and mutants thereof for improved antibody detection
  • HCV NS3 recombinant antigens and mutants thereof for improved antibody detection

Examples

Experimental program
Comparison scheme
Effect test

example 1

nd Expression of HCV NS3 9NB49H

[0169]The nucleotide sequence (Seq ID 1) encoding amino acids 1192-1457 of HCV (Seq ID 2) was codon optimized for E. coli expression and cloned into a modified pET32a vector wherein the sequence encoding a thioredoxin fusion protein was eliminated, and replaced with Methionine (M). In addition, a carboxy-terminal hexahistidine tag was included to facilitate purification via immobilized metal affinity chromatography (IMAC). E. coli BL21(DE3) cells were transformed with purified plasmid DNA and transformants screened. The resulting plasmid was designated p9NB49H and the protein expressed therefrom was designated as 9NB49H.

[0170]Protein expression was achieved by culturing the p9NB49H-transformed E. coli BL21(DE3) cells in terrific broth (TB) medium. Cells were grown in shake flasks to an OD600 nm of 0.50 and then induced with 1 mM IPTG and grown at 25-37° C. for approximately three hours until an OD600 nm of approximately 3.5 was obtained. Cells were har...

example 2

nd Expression of HCV NS3 Nbt-9NB49H

[0171]The nucleotide sequence encoding the NS3 9NB49H protein described in Example 1 was subcloned into a modified pET32a plasmid wherein the open reading frame encodes an amino-terminal biotinylation tag (MSGLNDIFEAQKIEWHE) with a GSGSNSM-linker sequence upstream of the NS3-encoding sequence followed by a carboxyl-terminal hexahistidine tag followed by a stop codon. The resulting plasmid was designated pNbt-9NB49H. The biotinylation tag, described by Beckett et al. (Protein Science, 8(4):921-929, 1999) permits site-specific biotin incorporation via a biotin ligase enzyme encoded by the E. coli BirA gene. E. coli BL21(DE3) cells were co-transformed with the pNbt-9NB49H expression plasmid and a second plasmid (pBirAcm) expressing the biotin ligase under control of an IPTG inducible promoter. Cells were grown in shake flasks at 37° C. in Terrific Broth with biotin added to 0.050 mM final concentration to an OD600 nm of 0.50 and then induced with 1 mM...

example 3

nd Expression of HCV NS3 9NB49H-Cbt

[0172]The nucleotide sequence encoding the NS3 9NB49H protein described in Example 1, was subcloned into a modified pET32a vector wherein the open reading frame encodes N-terminal methionine followed by NS3 followed by a GSGSG-linker and a hexahistidine tag followed by a GG-linker and the biotinylation tag (GLNDIFEAQKIEWHE) and finally the stop codon. The resulting plasmid was designated p9NB49H-Cbt. Protein expression and biotinylation was performed as described in Examples 1 and 2.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present disclosure relates to polypeptides, including fusions thereof, nucleic acids, vectors, host cells, immunodiagnostic reagents, kits, and immunoassays for use detecting the presence of HCV antibodies. More specifically, the present invention describes specific NS3 antigens that can be used for the detection of anti-HCV antibodies.

Description

FIELD OF THE INVENTION[0001]The present disclosure relates to polypeptides, including fusions thereof, nucleic acids, vectors, host cells, immunodiagnostic reagents, kits, and immunoassays for use detecting the presence of HCV antibodies.BACKGROUND OF THE INVENTION[0002]According to WHO statistics, as many as 170 million people worldwide are infected by hepatitis C virus (HCV), a viral infection of the liver. 75 to 85% of persons infected with HCV progress to chronic infection, approximately 20% of these cases develop complications of chronic hepatitis C, including cirrhosis of the liver or hepatocellular carcinoma after 20 years of infection. The current recommended treatment for HCV infections is a combination of interferon and ribavirin drugs, however the treatment is not effective in all cases and liver transplantation is indicated in hepatitis C-related end-stage liver disease. At present, there is no vaccine available to prevent HCV infection, therefore all precautions to avoi...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): C12N9/14G01N33/576C07K14/005
CPCC12N2800/22C12N2770/24222C07K2319/21C12N9/14C07K14/005G01N2469/20G01N33/5767C07K2319/20
Inventor MUERHOFF, A. SCOTTMAROHNIC, CHRISTOPHERBIRKENMEYER, LARRYPROSTKO, JOHNBOGDAN, M. FELICIAGUTIERREZ, ROBIN
Owner ABBOTT LAB INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com